“Our reader study demonstrated that the concurrent use of AI improved sensitivity, specificity and reading time when reading DBT with digital or synthetic 2D images,” according to Dr. Conant, principal investigator and lead author of the study. “These findings show improved cancer detection benefiting our patients as well as improved efficiency important for radiologists.
Events and clinical presentations throughout the meeting will feature experts who can discuss clinical perspectives and experience using ProFound AI in daily practice:
Monday, December 2: An investor luncheon and an evening reception, “AI After Dark,” will feature leading experts who will provide real-world experience and clinical perspectives in breast health solutions powered by artificial intelligence. The investor luncheon will be webcast and available online via this link.
Tuesday, December 3: Innovation Theater Presentation, “Advances in AI for personalized breast cancer screening using image-based short-term risk assessment,” will be presented by Mikael Eriksson, PhD, Karolinska Institutet.
Wednesday, December 4: AI Theater Presentation, “Advancements in Mammography for Cancer Detection and Risk Prediction” will be presented by Senthil Periaswamy, PhD, Chief Research Scientist, VP of Clinical Innovation, iCAD, Inc.
Leading experts will also be available in the main iCAD booth (#3929 in the south hall) daily throughout the meeting to offer live demonstrations with the technology. ProFound AI will also be featured in major PACS company exhibits at the meeting.
ProFound AI for DBT was FDA-cleared, CE marked, and Health Canada licensed in 2018. ProFound AI for 2D Mammography was CE marked in July 2019. For more information, visit www.icadmed.com.
Back to HCB News